What drugs does HETERO LABS LTD VI make?

HETERO LABS LTD VI has 7 FDA-approved drugs.

What therapeutic areas does HETERO LABS LTD VI focus on?

HETERO LABS LTD VI focuses primarily on Oncology.

← Back

Data updated: Jun 28, 2026

HETERO LABS LTD VI

Generics

Oncology

HETERO LABS LTD VI is a generic drug manufacturer focused on Oncology.

2024

Since

Drugs

Trials

New Drugs (2yr)

HETERO LABS LTD VI's Key Drugs

HETERO LABS LTD VI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HETERO LABS LTD VI's Recent FDA Approvals

HETERO LABS LTD VI secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA

2024-08-26

bortezomib

1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

HETERO LABS LTD VI's Therapeutic Areas

HETERO LABS LTD VI's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%

4 drugs

HETERO LABS LTD VI's Top Competitors

HETERO LABS LTD VI's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.